UA27031A1 - Похідhі 3(2h)піридазиhоhу або їх фармацевтичhо прийhятhі солі, що мають протитромботичhу, позитивhу іhотропhу, судиhорозширювальhу дію й аhтиалергічhу активhість та фармацевтичhа композиція hа їх осhові - Google Patents

Похідhі 3(2h)піридазиhоhу або їх фармацевтичhо прийhятhі солі, що мають протитромботичhу, позитивhу іhотропhу, судиhорозширювальhу дію й аhтиалергічhу активhість та фармацевтичhа композиція hа їх осhові

Info

Publication number
UA27031A1
UA27031A1 UA5010505A UA5010505A UA27031A1 UA 27031 A1 UA27031 A1 UA 27031A1 UA 5010505 A UA5010505 A UA 5010505A UA 5010505 A UA5010505 A UA 5010505A UA 27031 A1 UA27031 A1 UA 27031A1
Authority
UA
Ukraine
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
acceptable salts
antithrombotic
basis
Prior art date
Application number
UA5010505A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Танікава Кейзо
Саіто Акіра
Матсумото Такасі
Сакода Ріозо
Тсурузое Hабутомо
Сікада Кен-Іті
Original Assignee
Ніссан Кемікал Індастріз Лтд
Ниссан Кемикал Индастриз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ніссан Кемікал Індастріз Лтд, Ниссан Кемикал Индастриз Лтд filed Critical Ніссан Кемікал Індастріз Лтд
Publication of UA27031A1 publication Critical patent/UA27031A1/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
UA5010505A 1990-04-25 1991-04-19 Похідhі 3(2h)піридазиhоhу або їх фармацевтичhо прийhятhі солі, що мають протитромботичhу, позитивhу іhотропhу, судиhорозширювальhу дію й аhтиалергічhу активhість та фармацевтичhа композиція hа їх осhові UA27031A1 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10991490 1990-04-25
PCT/JP1991/000517 WO1991016314A1 (fr) 1990-04-25 1991-04-19 Derive de pyridazinone

Publications (1)

Publication Number Publication Date
UA27031A1 true UA27031A1 (uk) 2000-02-28

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
UA5010505A UA27031A1 (uk) 1990-04-25 1991-04-19 Похідhі 3(2h)піридазиhоhу або їх фармацевтичhо прийhятhі солі, що мають протитромботичhу, позитивhу іhотропhу, судиhорозширювальhу дію й аhтиалергічhу активhість та фармацевтичhа композиція hа їх осhові

Country Status (17)

Country Link
US (3) US5202323A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0482208B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH07107055B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR970002876B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE194835T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU634655B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2053863C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69132329T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0482208T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2149761T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3034331T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU208124B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2054004C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW204348B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA27031A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1991016314A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA913134B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002876B1 (ko) * 1990-04-25 1997-03-12 닛산가가꾸고오교 가부시끼가이샤 피리다지논 유도체
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
EP0717734B1 (en) * 1993-09-06 1998-11-18 Ishihara Sangyo Kaisha, Ltd. Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
TW326041B (en) * 1993-12-16 1998-02-01 Nippon Nouyaku Kk Pyridazinone derivatives, their production process and their use for inhibition of platelet aggregation
ES2147841T3 (es) * 1994-01-25 2000-10-01 Nissan Chemical Ind Ltd Derivados de piridazinona.
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
PT907650E (pt) 1996-06-27 2003-04-30 Janssen Pharmaceutica Nv N-¬4-(heteroarilmetil)fenil|heteroarilaminasc
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
WO1999011268A1 (fr) 1997-08-28 1999-03-11 Yoshitomi Pharmaceutical Industries, Ltd. Agents promoteurs et agents potentialisateurs de la neovascularisation
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
EP1123704B1 (en) * 1998-09-01 2004-08-04 Nissan Chemical Industries, Ltd. Remedies for spinal canal stenosis
NZ512754A (en) * 1998-12-07 2002-10-25 Nissan Chemical Ind Ltd Remedial agent for erectile dysfunction containing a 3(2H)-pyridazinone derivative
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
CZ20032013A3 (cs) * 2001-04-05 2003-12-17 Torrent Pharmaceuticals Ltd. Heterocyklické sloučeniny pro léčení vaskulárních diabetických komplikací a komplikací souvisejících se stářím
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
WO2002094320A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions therapeutiques permettant de reparer la chondropathie
MXPA03010679A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1663197B1 (en) * 2003-09-09 2007-12-05 Fumapharm AG The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
WO2005063250A1 (ja) * 2003-12-26 2005-07-14 Nissan Chemical Industries, Ltd. 好中球増多抑制剤
AU2005210326B2 (en) * 2004-02-09 2009-10-22 Nissan Chemical Industries, Ltd. Drug for inhibiting vascular intimal hyperplasia
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010074090A1 (ja) 2008-12-25 2010-07-01 日産化学工業株式会社 ピリダジン-3(2h)-オン化合物塩酸塩の結晶及びその製造方法
MY162507A (en) 2009-06-29 2017-06-15 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
CN102740855B (zh) 2010-02-12 2013-11-27 大正制药株式会社 缓释制剂
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションIncyte Corporation PI3Kδ阻害剤としての縮合誘導体
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SG10201601589QA (en) 2011-09-02 2016-04-28 Incyte Corp Heterocyclylamines as pi3k inhibitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
JP6360176B2 (ja) 2013-09-12 2018-07-18 アリオス バイオファーマ インク. ピリダジノン化合物およびその用途
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
HUE060953T2 (hu) 2015-02-27 2023-04-28 Incyte Holdings Corp Eljárások PI3K inhibitor elõállítására
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
PE20211208A1 (es) 2018-06-01 2021-07-05 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
EP0186817B1 (en) * 1984-12-10 1989-08-02 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
ES2031821T3 (es) * 1985-10-17 1993-01-01 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
KR970002876B1 (ko) * 1990-04-25 1997-03-12 닛산가가꾸고오교 가부시끼가이샤 피리다지논 유도체

Also Published As

Publication number Publication date
CA2053863C (en) 1996-10-29
KR920701169A (ko) 1992-08-11
GR3034331T3 (en) 2000-12-29
ES2149761T3 (es) 2000-11-16
DK0482208T3 (da) 2000-09-18
WO1991016314A1 (fr) 1991-10-31
US5314883A (en) 1994-05-24
DE69132329T2 (de) 2000-11-30
RU2054004C1 (ru) 1996-02-10
AU7651191A (en) 1991-11-11
EP0482208B1 (en) 2000-07-19
KR970002876B1 (ko) 1997-03-12
TW204348B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-04-21
HUT60253A (en) 1992-08-28
AU634655B2 (en) 1993-02-25
EP0482208A4 (en) 1992-10-07
JPH07107055B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-11-15
ZA913134B (en) 1992-04-29
EP0482208A1 (en) 1992-04-29
HU913497D0 (en) 1992-01-28
DE69132329D1 (de) 2000-08-24
US5318968A (en) 1994-06-07
US5202323A (en) 1993-04-13
ATE194835T1 (de) 2000-08-15
HU208124B (en) 1993-08-30
CA2053863A1 (en) 1991-10-26

Similar Documents

Publication Publication Date Title
UA27031A1 (uk) Похідhі 3(2h)піридазиhоhу або їх фармацевтичhо прийhятhі солі, що мають протитромботичhу, позитивhу іhотропhу, судиhорозширювальhу дію й аhтиалергічhу активhість та фармацевтичhа композиція hа їх осhові
GR3029603T3 (en) Cytotoxic stilbene derivatives and pharmaceutical composition containing them.
GR3032311T3 (en) Stilbene derivatives and pharmaceutical compositions containing them
NZ335013A (en) Compositions comprising cytosine derivatives for the treatment of cancer
ATE56454T1 (de) Cephalosporinderivate.
GR3034542T3 (en) 4,5-diaryloxazole derivatives
GR3018086T3 (en) Heterocyclic bisphosphonic acid derivatives.
SG50457A1 (en) Trifluoromethylketone derivatives processes for preparation thereof and use thereof
ES557061A0 (es) Un procedimiento para preparar un derivado de 1,5-benzotiazepina
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
UA21900A (uk) Похідhі глутатіоhу або їх фармацевтичhо прийhятhі солі, які проявляють протизапальhу, протиалергійhу та гепатотропhу активhість, і спосіб їх одержаhhя
EP0205334A3 (en) Benzazepine derivatives
EP0408044A3 (en) Anti-inflammatory and/or anti-allergic composition comprising glutathione derivatives
CA2204204A1 (en) Carbohydrate derivatives
DE3567651D1 (en) Novel 1,5-benzothiazepine derivative, processes for preparing the same and pharmaceutical compositions
YU140391A (sh) 6-supstituisani-heksahidrobenz (cd)-indoli
CA2195031A1 (en) Quinolinone derivative and anti-allergic agent with said quinolinone derivative as the active ingredient
NZ334119A (en) Use of pentynoic acid derivatives as neurotrophic and antiproliferative agents
ES8707951A1 (es) Derivados de tetrazol
GR3031767T3 (en) Cyclopropane derivatives and antiviral agents containing the same.
DE68927286D1 (de) Pyrrolidin-Derivate
CA2187402A1 (en) Quinoxaline Derivatives for Treating Tinnitus
SG4595G (en) Use of 2-oxo-imidazolidine derivatives in the prophylaxis and treatment of heart failure
GB1495890A (en) Thioxanthenecarboxylic acid derivative
MY103748A (en) A new antitumor agent obtained by microbial stereoselective reduction of 4-deoxy-4-iododoxorubicin